Could a Weight-Loss drug curb meth addiction? new trial aims to find out

NCT ID NCT07204249

Recruiting now Disease control Sponsor: San Francisco Department of Public Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether semaglutide (Wegovy), a drug used for diabetes and weight loss, can help people with moderate to severe methamphetamine use disorder cut back or stop using. The trial has two parts: a small pilot study with 25 people, followed by a larger randomized trial with 162 participants who will receive either semaglutide or a placebo. Researchers will measure meth use through hair tests, urine tests, and self-reports over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (Wegovy)
What this could lead to: If it works, this could point toward a new medication to help people reduce or stop methamphetamine use.
What could go wrong: This is an early phase 2 trial with only 162 people, so results may not apply widely. Side effects from semaglutide are possible, and the drug may not reduce meth use as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METHAMPHETAMINE-DEPENDENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

methamphetamine dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METHAMPHETAMINE-DEPENDENCE

Contacts and locations

Locations

Center on Substance Use and Health
RECRUITING

San Francisco, California, 94102, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.